EUVIMEDEUVIMED entdecken
Crossref

A ROS ‐Responsive Hydrogel Microneedle System Co‐Delivering Tofacitinib and Azelaic Acid for Enhanced Targeted Therapy of Rosacea

Yong Yu, Xiaoxia Ding, Yibin Fan iD, Youming Huang iD, Danfeng Xu

Journal of Biomedical Materials Research Part A · 2026-02 · 114 (2)

DOI: 10.1002/jbma.70035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part A, online erschienen am 26.01.2026. Verfasst von Yong Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Plastic and Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzh…. Hauptthemen laut MEDLINE: Rosacea, Piperidines, Dicarboxylic Acids, Hydrogels. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: the Medical and Health Science and Technology Program of Zhejiang Province, Zhejiang Provincial Medical and Health Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rosacea is a chronic inflammatory skin condition primarily affecting the face, characterized by symptoms such as persistent redness, visible blood vessels, papules, and pustules. Current treatments, including topical agents and systemic antibiotics, are often limited by poor skin penetration, local irritation, or the risk of systemic adverse effects and antibiotic resistance. This study designed, fabricated, and evaluated a novel ROS‐responsive hydrogel microneedle (MN) system for the co‐delivery of tofacitinib (a JAK inhibitor) and azelaic acid (A ZA) to treat rosacea. The hypothesis was that this Tofa/AZA@HPA‐MN platform would enable triggered drug release in the high‐ROS environment of inflamed skin, enhancing therapeutic efficacy and safety compared to conventional topical delivery. Topical tofacitinib and AZA were found to ameliorate LL37‐induced murine rosacea‐like inflammation, partly via JAK/STAT inhibition. A ROS‐responsive hydrogel (HPA) was synthesized and fabricated into robust MNs, demonstrating effective skin penetration and retention. In vitro, these MNs displayed accelerated drug release under oxidative conditions and protected keratinocytes from H 2 O 2 ‐induced stress. In vivo, the Tofa/AZA@HPA‐MNs proved superior to conventional topical Tofa + AZA and empty MNs, significantly reducing inflammation, tissue ROS levels, and JAK/STAT activation in a rosacea model. Crucially, safety assessments revealed no significant systemic toxicity, addressing the major translational concern regarding the systemic risks of JAK inhibitors. The developed system offers a promising, safe, and more effective targeted therapeutic strategy for rosacea by enabling triggered drug release directly within the inflamed skin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RosaceaPiperidinesDicarboxylic AcidsHydrogelsReactive Oxygen SpeciesPyrimidinesAnimalsMicroneedle Drug DeliveryHumansMiceAdministration, Cutaneous

Stichwörter der Autor:innen

ROS‐responsiveazelaic aciddrug deliverymicroneedlesrosaceatofacitinib

Substanzen

azelaic acidtofacitinibPiperidinesDicarboxylic AcidsHydrogelsReactive Oxygen SpeciesPyrimidines

Autor:innen und Institutionen

  • Center for Plastic and Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

ORCID-Profile: Yibin Fan, Youming Huang

Förderung

  • the Medical and Health Science and Technology Program of Zhejiang Province
  • Zhejiang Provincial Medical and Health Science and Technology Project

Zitieren

APA

Yu, Y., Ding, X., Fan, Y., Huang, Y., & Xu, D. (2026). A ROS ‐Responsive Hydrogel Microneedle System Co‐Delivering Tofacitinib and Azelaic Acid for Enhanced Targeted Therapy of Rosacea. Journal of Biomedical Materials Research Part A, 114(2). https://doi.org/10.1002/jbma.70035

Vancouver

Yu Y, Ding X, Fan Y, Huang Y, Xu D. A ROS ‐Responsive Hydrogel Microneedle System Co‐Delivering Tofacitinib and Azelaic Acid for Enhanced Targeted Therapy of Rosacea. Journal of Biomedical Materials Research Part A. 2026;114(2). doi:10.1002/jbma.70035

BibTeX
@article{Yu2026,
  author = {Yu, Yong and Ding, Xiaoxia and Fan, Yibin and Huang, Youming and Xu, Danfeng},
  title = {A ROS ‐Responsive Hydrogel Microneedle System Co‐Delivering Tofacitinib and Azelaic Acid for Enhanced Targeted Therapy of Rosacea},
  journal = {Journal of Biomedical Materials Research Part A},
  year = {2026},
  volume = {114},
  number = {2},
  doi = {10.1002/jbma.70035}
}
Kostenlos starten →